The Chip in the Skull

The public face of brain-computer interfaces is Neuralink, Elon Musk’s venture. But in 2026 it was China’s regulator that granted what was billed as the world’s first approval of an invasive brain-computer interface for use beyond clinical trials, a device called NEO, developed by Neuracle Technology with Tsinghua University.^[1][2]

NEO takes a deliberately less invasive route than Neuralink’s: eight sensors resting on the dura, the membrane over the brain, rather than electrodes pushed into the cortex.^[1] The results are tangible. Since October 2023 the team behind it has carried out 36 implantations, and one paralysed patient regained enough finger dexterity, after eleven months of rehabilitation with the implant and a robotic glove, to write his own name.^[1]

A paralysed man learned to write his name again with eight sensors on the surface of his brain. That is the promise, and the whole distance still to travel.

More than one program

China is running parallel efforts. A separate semi-invasive system, Beinao-1, from the Chinese Institute for Brain Research and NeuCyber NeuroTech, had been implanted in five patients by August 2025; one, with ALS, could translate thought into more than sixty common Chinese words, described as the first time a wireless, fully implanted interface decoded Chinese.^[3] The state is behind it: brain-computer interfaces are named among priority industries, and NEO has been assigned a medical-insurance billing code.^[1] For scale, Neuralink had reached 21 patients worldwide by early 2026.^[4]

The caveats are large and apply to everyone. NEO is on the surface of the brain rather than in the cortex, so comparing it to Neuralink is apples to oranges, not simply ahead or behind. Patient numbers on all sides are tiny and the trials are early-feasibility, not efficacy. This is a frontier at its very beginning.

What we do with this

Brain-computer interfaces are among the most speculative bets in medicine, and China’s presence at the front is the signal worth taking from this, not a claim that any device is proven. A first regulatory approval, a state industrial designation and an insurance code together suggest China intends to build a clinical pathway and a market, not just publish papers, and that infrastructure may matter more than any single implant. We treat the field as early-stage optionality with obvious dual-use weight, hold the hype firmly apart from the handful of real patients, and note that on a frontier this young, the country that builds the regulatory and reimbursement rails first may shape the industry that eventually grows on them.